Prof. Jinluan Li

Quality Control Office of Fujian Provincial Cancer Hospital,

National Training Base for Radiation Oncology Specialty，China

Associate Professor, Deputy Chief Physician

Email: [email protected]

Qualifications

2014 Postdoctoral research, UNMC, USA

2011 Ph.D., Peking University, China

2004 B.Sc., Fujian Medical University, China

Publications (selected)

1. Liu Y, Chen Y, Tang L, et al. KBTBD11 suppresses hepatocellular carcinoma by targeting ENO1-mediated glycolysis[J]. Journal of Translational Medicine, 2025, 23(1): 1087.
2. Zeng Y, Lin F, Li H, et al. Melanoma GPA as a novel prognostic scoring model based on initial brain metastasis velocity[J]. Scientific Reports, 2025, 15(1): 29446.
3. Zhuang Q, Li H, Tang L, et al. Safety and efficacy analysis of neoadjuvant radiotherapy combined with concurrent paclitaxel plus nedaplatin versus other platinum-based chemotherapy for thoracic segmental esophageal squamous cell carcinoma[J]. Frontiers in Oncology, 2025, 15: 1582481.
4. Chen J, Xu J, Wang Q, et al. A dual-targeted small-molecule photosensitizer with enhanced dual antitumor and anti-vascular effect for metastatic advanced prostate cancer photodynamic therapy[J]. Dyes and Pigments, 2025, 232: 112476.
5. Yu Y, Li H, Hu N, et al. Global burden and health inequality of nutritional deficiencies from 1990 to 2019[J]. Frontiers in nutrition, 2024, 11: 1470713.
6. Zhou H, Wang L, Lin Z, et al. Methylglyoxal from gut microbes boosts radiosensitivity and radioimmunotherapy in rectal cancer by triggering endoplasmic reticulum stress and cGAS-STING activation[J]. Journal for Immunotherapy of Cancer, 2023, 11(11): e007840.
7. Zhang X, Zeng Y, Li H, et al. A Modified NAR Scoring Model Incorporating Immune Infiltration Characteristics to Better Predict Long-Term Survival Following Neoadjuvant Radiotherapy in Rectal Cancer[J]. Life, 2023, 13(11): 2106.
8. Xiao Y, Li J, Wu J. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma[J]. BMC Medical Genomics, 2023, 16(1): 177.
9. Zhou H, Chen Y, Xiao Y, et al. Evaluation of the ability of fatty acid metabolism signature to predict response to neoadjuvant chemoradiotherapy and prognosis of patients with locally advanced rectal cancer[J]. Frontiers in Immunology, 2022, 13: 1050721.
10. Li J, Li H, Wu Q, et al. Analysis of prognosis and treatment decisions for patients with second primary lung cancer following esophageal cancer[J]. Frontiers in Oncology, 2022, 12: 777934.
11. Qing-Qin P, Jin-Luan L I, Pei-Ling X I N, et al. Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer[J]. Neoplasma, 2021, 68(4).
12. Zhao L, Chen P, Fu K, et al. Concordance of PD-L1 status between image-guided percutaneous biopsies and matched surgical specimen in non-small cell lung cancer[J]. Frontiers in Oncology, 2021, 10: 551367.
13. Xu C W, Wang W X, Wang D, et al. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with EGFR exon 20 insertion mutation: a multicenter study[J]. Translational Lung Cancer Research, 2020, 9(5): 1853.
14. Lin P, Lin X, Li J, et al. Patterns of supraclavicular area failure after mastectomy in breast cancer patients: Implications for target volume delineation[J]. Journal of International Medical Research, 2020, 48(9): 0300060520953315.
15. Lei L, Wang W, Zhu Y, et al. Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: a multi‐center study[J]. Cancer Medicine, 2020, 9(1): 12-18.
16. Huang Y, Lin Y, Li J, et al. Role of postoperative radiotherapy in pT3N0 rectal cancer: A risk‐stratification system based on population analyses[J]. Cancer medicine, 2019, 8(3): 1024-1033.
17. Zhang X, Li J, Peng Q, et al. Association of markers of systemic and local inflammation with prognosis of patients with rectal cancer who received neoadjuvant radiotherapy[J]. Cancer Management and Research, 2018: 191-199.
18. Tang L, Wu J, Cai S, et al. Prolyl hydroxylase domain 3 influences the radiotherapy efficacy of pancreatic cancer cells by targeting hypoxia-inducible factor-1α[J]. OncoTargets and therapy, 2018: 8507-8515.
19. Kong X, Zhang X, Huang Y, et al. Characteristics and prognostic factors of colorectal mucinous adenocarcinoma with signet ring cells[J]. Cancer management and research, 2017: 573-580.
20. Li Y H, Li J L, Zhu X G, et al. Associations of tumor regression grade with outcomes in patients with locally advanced rectal cancer treated with preoperative two-week course of radiotherapy[J]. Oncotarget, 2017, 8(59): 100165.
21. Shao L, Peng Q, Du K, et al. Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy[J]. Cancer Management and Research, 2017: 249-258.
22. Li J, Lin X, Zhuang L, et al. Establishment of a risk scoring system for predicting locoregional recurrence in T1 to T2 node-negative breast cancer patients treated with mastectomy: Implications for postoperative radiotherapy[J]. Medicine, 2017, 96(26): e7343.

Profile Details

https://pubmed.ncbi.nlm.nih.gov/38168553/
https://loop.frontiersin.org/people/1142830/bio
https://www.researchgate.net/profile/Jin-Luan-Li
https://orcid.org/0000-0002-3533-898X